ContractShareholders’ Agreement • June 29th, 2004 • Xenova Group PLC • Biological products, (no disgnostic substances) • England
*CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY AN *.
DISTRIBUTION AGREEMENTDistribution Agreement • June 29th, 2004 • Xenova Group PLC • Biological products, (no disgnostic substances)
THIS DISTRIBUTION AGREEMENT is entered into as of July 23, 2002 (the “Effective Date”) by and between KS Biomedix Plc. (“KS”), a company located at 1 Occam court surrey research park, Guilford surrey GU2 7HJ United Kingdom and Medison Pharma Ltd, 10, Hashiloach St., Petach Tikva, (“Distributor”), an Israeli Corporation.
ContractLicensing and Supply Agreement • June 29th, 2004 • Xenova Group PLC • Biological products, (no disgnostic substances) • England
* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY AN *.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 29th, 2004 • Xenova Group PLC • Biological products, (no disgnostic substances) • New York
This SECURITIES PURCHASE AGREEMENT (“Agreement”) is dated as of the 25th day of November, 2003 by and among Xenova Group plc (the “Company”), the several purchasers named in the attached Exhibit A (individually, a “Purchaser” and collectively, the “Purchasers”) and Bingham McCutchen LLP as Escrow Agent (the “Escrow Agent”).
PLACING AND OPEN OFFER AGREEMENTOffer Agreement • June 29th, 2004 • Xenova Group PLC • Biological products, (no disgnostic substances) • England
DRUG DELIVERY PATENT SUBLICENSE AGREEMENTPatent Sublicense Agreement • June 29th, 2004 • Xenova Group PLC • Biological products, (no disgnostic substances) • New Jersey
This Drug Delivery Patent Sublicense Agreement (Agreement) is entered into as of May 2002 (Effective Date) by and between Amersham Health A.S. (formerly Nycomed Imaging A.S.), a company organized under the laws of Norway with offices at Nycoveien 2, Post Office Box 4220, Torshov, N-0401, Oslo, Norway (AH), and KS Avicenna, Inc. (formerly INTELLIgene Expressions Inc.) a corporation organized under the laws of Canada, with offices at Edmonton Research Park, 1938-94 Street, Edmonton, Alberta, Canada T6N 1J3 (KSA).
ContractAgreement • June 29th, 2004 • Xenova Group PLC • Biological products, (no disgnostic substances) • England
* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY AN *.
PUBLIC HEALTH SERVICE AMENDMENT L-007-96/1Xenova Group PLC • June 29th, 2004 • Biological products, (no disgnostic substances)
This Amendment of the Non-Exclusive Patent License, L-007-96/0 (“Agreement”), L-007-96/1 (“Amendment”), is made between the National Institutes of Health (“NIH”), the Centers for Disease Control and Prevention (“CDC”), or the Food and Drug Administration (“FDA”), hereinafter singly or collectively referred to as (“PHS”), agencies of the United States Public Health Service within the Department of Health and Human Services (“DHHS”) through the Office of Technology Transfer, NIH, having an address at 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804, U.S.A., and Amersham Health Inc. (“Licensee”), having an office at 101 Carnegie Center, Princeton, New Jersey 08540).
KS Biomedix Holdings PLCXenova Group PLC • June 29th, 2004 • Biological products, (no disgnostic substances)
ContractLicence Agreement • June 29th, 2004 • Xenova Group PLC • Biological products, (no disgnostic substances) • England
* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY AN *.
CHLOROQUINE PATENT SUBLICENSE AGREEMENTChloroquine Patent Sublicense Agreement • June 29th, 2004 • Xenova Group PLC • Biological products, (no disgnostic substances) • New Jersey
This Chloroquine Patent Sublicense Agreement (Agreement) is entered into as of May , 2002 by and between Amersham Health A.S. (formerly Nycomed Imaging A.S.), a company organized under the laws of Norway with offices at Nycoveien 2, Post Office Box 4220, Torshov, N-0401, Oslo, Norway (AH), and KS Avicenna (formerly INTELLIgene Expressions Inc.), a corporation organized under the laws of Canada, with offices at Edmonton Research Park, 1938-94 Street, Edmonton, Alberta, Canada T6N 1J3 (KSA).
November 10, 2003 PERSONAL AND CONFIDENTIAL Mr. Daniel Abrams Group Finance Director Xenova Group plc Slough Berkshire SL1 4NL Dear Mr. Abrams:Non-Disclosure Agreement • June 29th, 2004 • Xenova Group PLC • Biological products, (no disgnostic substances) • New York
This letter will confirm the understanding and agreement (the “Agreement”) between ThinkEquity Partners LLC (“TEP”) and Xenova Group plc (the “Company”) as follows:
NATIONAL INSTITUTES OF HEALTH CENTERS FOR DISEASE CONTROL PATENT LICENSE AGREEMENT—EXCLUSIVE COVER PAGEPatent License Agreement • June 29th, 2004 • Xenova Group PLC • Biological products, (no disgnostic substances) • District of Columbia
Licensee agrees to the following Benchmarks for its performance under this Agreement and, within ten (10) days of achieving a Benchmark, shall notify PHS that the Benchmark has been achieved.
ContractLicense Agreement • June 29th, 2004 • Xenova Group PLC • Biological products, (no disgnostic substances) • New Jersey
* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY AN *.
